reserpine has been researched along with Diabetic Glomerulosclerosis in 7 studies
Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.
reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to compare the effects of an equivalent reduction in blood pressure produced by the angiotensin-converting enzyme (ACE) inhibitor spirapril (SPI) and an antihypertensive triple drug combination of hydralazine, reserpine and hydrochlorothiazide (HRH) on kidney function, proteinuria and renal structure in hypertensive diabetic rats." | 3.70 | Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats. ( Armini, L; Bardelli, M; Calci, M; Campanacci, L; Candido, R; Carretta, R; Fabris, B; Fazio, M; Fischetti, F, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 4 (57.14) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gangadhariah, MH | 1 |
| Luther, JM | 1 |
| Garcia, V | 1 |
| Paueksakon, P | 1 |
| Zhang, MZ | 2 |
| Hayward, SW | 1 |
| Love, HD | 1 |
| Falck, JR | 1 |
| Manthati, VL | 1 |
| Imig, JD | 1 |
| Schwartzman, ML | 1 |
| Zent, R | 1 |
| Capdevila, JH | 1 |
| Pozzi, A | 1 |
| Wang, S | 1 |
| Yang, S | 1 |
| Yang, H | 1 |
| Fan, X | 1 |
| Takahashi, T | 1 |
| Harris, RC | 1 |
| Mahnensmith, RL | 1 |
| O'Brien, RC | 1 |
| Cooper, ME | 1 |
| Jerums, G | 1 |
| Doyle, AE | 1 |
| Tang, Z | 1 |
| Shou, I | 1 |
| Wang, LN | 1 |
| Fukui, M | 1 |
| Tomino, Y | 1 |
| Fabris, B | 1 |
| Candido, R | 1 |
| Armini, L | 1 |
| Fischetti, F | 1 |
| Calci, M | 1 |
| Bardelli, M | 1 |
| Fazio, M | 1 |
| Campanacci, L | 1 |
| Carretta, R | 1 |
| Anderson, S | 1 |
| Rennke, HG | 1 |
| Garcia, DL | 1 |
| Brenner, BM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Delaying the Progression of Diabetic Nephropathy in Pima Indians[NCT00353600] | 25 participants (Anticipated) | Observational | 1994-08-19 | Completed | |||
| Renoprotection in Early Diabetic Nephropathy in Pima Indians[NCT00340678] | Phase 3 | 170 participants (Actual) | Interventional | 1995-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00340678)
Timeframe: 6 years after first treatment
| Intervention | *10^6 cubic microns (Mean) |
|---|---|
| Normoalbuminuria Losartan | 5.4 |
| Normoalbuminuria Placebo | 5.6 |
| Microalbuminuria Losartan | 6.4 |
| Microalbuminuria Placebo | 7.0 |
Participants were monitored for up to 6 years. This is the number of participants who had a decline in GFR to less than or equal to 60 ml/min or to half the baseline value in subjects that enter the study with a GFR of less than 120 ml/min during the time of observation. (NCT00340678)
Timeframe: Up to 6 years
| Intervention | participants (Number) |
|---|---|
| Normoalbuminuria Losartan | 2 |
| Normoalbuminuria Placebo | 2 |
| Microalbuminuria Losartan | 1 |
| Microalbuminuria Placebo | 4 |
1 review available for reserpine and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Diabetic nephropathy: a comprehensive approach.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Clinical Protocols; Clinical Tria | 1993 |
6 other studies available for reserpine and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Hypertension is a major contributor to 20-hydroxyeicosatetraenoic acid-mediated kidney injury in diabetic nephropathy.
Topics: Animals; Collagen; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 4; Diabetic Nephropathies; | 2015 |
Role of blood pressure and the renin-angiotensin system in development of diabetic nephropathy (DN) in eNOS-/- db/db mice.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Captopri | 2012 |
The effects of perindopril and triple therapy in a normotensive model of diabetic nephropathy.
Topics: Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blood Pressu | 1993 |
Effects of antihypertensive drugs or glycemic control on antioxidant enzyme activities in spontaneously hypertensive rats with diabetes.
Topics: Animals; Antihypertensive Agents; Antioxidants; Blood Glucose; Captopril; Catalase; Diabetes Mellitu | 1997 |
Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Diabetic | 1999 |
Short and long term effects of antihypertensive therapy in the diabetic rat.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Captopril; Diabetic Nephropathies; Drug Administra | 1989 |
Short and long term effects of antihypertensive therapy in the diabetic rat.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Captopril; Diabetic Nephropathies; Drug Administra | 1989 |
Short and long term effects of antihypertensive therapy in the diabetic rat.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Captopril; Diabetic Nephropathies; Drug Administra | 1989 |
Short and long term effects of antihypertensive therapy in the diabetic rat.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Captopril; Diabetic Nephropathies; Drug Administra | 1989 |